[go: up one dir, main page]

PE20091832A1 - Combinacion farmaceutica de un inhibidor de cmet y axl y un inhibidor de erbb - Google Patents

Combinacion farmaceutica de un inhibidor de cmet y axl y un inhibidor de erbb

Info

Publication number
PE20091832A1
PE20091832A1 PE2009000602A PE2009000602A PE20091832A1 PE 20091832 A1 PE20091832 A1 PE 20091832A1 PE 2009000602 A PE2009000602 A PE 2009000602A PE 2009000602 A PE2009000602 A PE 2009000602A PE 20091832 A1 PE20091832 A1 PE 20091832A1
Authority
PE
Peru
Prior art keywords
inhibitor
cmet
pharmaceutical combination
axl
alkyl
Prior art date
Application number
PE2009000602A
Other languages
English (en)
Inventor
Tona M Gilmer
James G Greger Jr
Li Liu
Hong Shi
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41257222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091832(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20091832A1 publication Critical patent/PE20091832A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

REFERIDA A UNA COMBINACION FARMACEUTICA QUE COMPRENDE: I) UN INHIBIDOR DE QUINASAS cMET Y AXL DE FORMULA (A), DONDE R1 ES ALQUILO C1-C6; R2 ES ALQUILO C1-C6 O -(CH2)n-N(R5)2; R5 ES ALQUILO C1-C6, O JUNTO AL ATOMO DE N FORMAN UN GRUPO MOROFOLINO, PIPERIDINILO O PIRAZINILO; R3 Y R4 SON Cl O F; n ES 2, 3 O 4; p ES 0 O 1; q ES 0, 1 O 2; Y II) UN INHIBIDOR DE ErB TAL COMO TRASTUZUMAB, CETUXIMAB O UN ANTICUERPO MONOCLONAL ANTI-ErB-3 HUMANO. PARTICULARMENTE, EL COMPUESTO DE FORMULA (A) ES (N1-{3-FLUORO-4-[(6-(METILOXI)-7-{[3-(4-MORFOLINIL)PROPIL]OXI}-4-QUINOLINIL)OXI]FENIL}-N1-(4-FLUOROFENIL)-1,1-CICLOPROPANODICARBOXAMIDA). DICHA COMBINACION ES UTIL EN EL TRATAMIENTO DE CANCER DE MAMA, PULMON, CABEZA Y CUELLO, PIEL, OVARIO, ENTRE OTROS
PE2009000602A 2008-05-05 2009-05-04 Combinacion farmaceutica de un inhibidor de cmet y axl y un inhibidor de erbb PE20091832A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5032208P 2008-05-05 2008-05-05

Publications (1)

Publication Number Publication Date
PE20091832A1 true PE20091832A1 (es) 2009-12-25

Family

ID=41257222

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000602A PE20091832A1 (es) 2008-05-05 2009-05-04 Combinacion farmaceutica de un inhibidor de cmet y axl y un inhibidor de erbb

Country Status (19)

Country Link
US (3) US20090274693A1 (es)
EP (1) EP2274304A4 (es)
JP (1) JP2011519941A (es)
KR (1) KR20110004462A (es)
CN (1) CN102083824A (es)
AR (1) AR071631A1 (es)
AU (1) AU2009244453B2 (es)
BR (1) BRPI0912582A2 (es)
CA (1) CA2723699A1 (es)
CL (1) CL2009001063A1 (es)
EA (1) EA020779B1 (es)
IL (1) IL209057A0 (es)
MX (1) MX2010012101A (es)
PE (1) PE20091832A1 (es)
SG (1) SG190623A1 (es)
TW (1) TW201006829A (es)
UY (1) UY31800A (es)
WO (1) WO2009137429A1 (es)
ZA (1) ZA201007722B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2833852C (en) 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
PL2387563T5 (pl) 2009-01-16 2023-03-13 Exelixis, Inc. Sól jabłczanowa N-(4-{[6,7-bis(metyloksy)chinolin-4-ylo]oksy}fenylo-N′-(4-fluorofenylo)cykloproano-1,1-dikarboksyamidu oraz jej krystaliczne postaci do leczenia raka
CN104788564A (zh) 2009-03-25 2015-07-22 健泰科生物技术公司 抗-fgfr3抗体及其使用方法
WO2011003853A2 (en) 2009-07-06 2011-01-13 Boehringer Ingelheim International Gmbh Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
WO2011014457A1 (en) * 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
WO2011014872A2 (en) * 2009-07-31 2011-02-03 The Johns Hopkins University Compositions and methods for diagnosing, treating or preventing neoplasias
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
SI2719708T1 (en) * 2009-11-13 2018-03-30 Daiichi Sankyo Europe Gmbh Material and methods for treating or preventing HER-3-related diseases
US9724342B2 (en) 2010-07-16 2017-08-08 Exelixis, Inc. C-met modulator pharmaceutical compositions
BR112013004012B1 (pt) 2010-08-20 2021-03-23 Novartis Ag Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
SI2621481T2 (sl) 2010-09-27 2023-02-28 Exelixis, Inc., Dvojni inhibitorji MET in VEGF za zdravljenje proti kastraciji odpornega raka prostate in osteoblastnih kostnih metastaz
AU2011348256A1 (en) * 2010-12-23 2013-07-11 Nestec S.A. Drug selection for malignant cancer therapy using antibody-based arrays
CN102532109B (zh) * 2010-12-27 2015-05-13 浙江海正药业股份有限公司 一种拉帕替尼及其盐的合成方法
CN102093421B (zh) * 2011-01-28 2014-07-02 北京康辰药业有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
EP2673262B1 (en) 2011-02-10 2021-11-03 Exelixis, Inc. Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
UA115527C2 (uk) * 2011-05-02 2017-11-27 Екселіксіс, Інк. Застосування n-(4-{[6,7-бic(мeтилoкcи)xiнoлiн-4-iл]oкcи}фeнiл)-n'-(4-фтopфeнiл)циклoпpoпaн-1,1-дикapбoкcaмiду для лікування нирково-клітинної карциноми (варіанти)
CA2848512A1 (en) 2011-09-22 2013-03-28 Exelixis, Inc. Method for treating osteoporosis
BR112014009302B1 (pt) 2011-10-20 2020-04-28 Exelis Inc Us/Us processo para preparar derivados de quinolina
WO2013074633A1 (en) * 2011-11-14 2013-05-23 Cephalon, Inc. Uracil derivatives as axl and c-met kinase inhibitors
WO2013084147A2 (en) * 2011-12-05 2013-06-13 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
TWI594986B (zh) 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
NZ627586A (en) 2012-01-31 2016-08-26 Daiichi Sankyo Co Ltd Pyridone derivatives
US9861624B2 (en) 2012-05-02 2018-01-09 Exelixis, Inc. Method of treating cancer
CN103664879A (zh) * 2012-09-17 2014-03-26 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103705521A (zh) * 2012-09-28 2014-04-09 韩冰 一类治疗脑梗塞的化合物及其用途
WO2014093750A1 (en) * 2012-12-14 2014-06-19 Glaxosmithkline Llc Method of administration and treatment
WO2014145715A1 (en) 2013-03-15 2014-09-18 Exelixis, Inc. Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
KR102060540B1 (ko) 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
WO2014165786A1 (en) 2013-04-04 2014-10-09 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
TWI649308B (zh) * 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
EP3057608A4 (en) * 2013-10-14 2017-10-11 Janssen Biotech, Inc. Cysteine engineered fibronectin type iii domain binding molecules
RS60150B1 (sr) * 2014-02-04 2020-05-29 Astellas Pharma Inc Medicinska kompozicija koja obuhvata diamino heterociklično jedinjenje karboksamida kao aktivni sastojak
CA3181899A1 (en) 2014-02-14 2015-08-20 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
WO2015142928A1 (en) 2014-03-17 2015-09-24 Exelixis, Inc. Dosing of cabozantinib formulations
US9980966B2 (en) * 2014-04-03 2018-05-29 Merck Patent Gmbh Combinations of cancer therapeutics
KR102223502B1 (ko) 2014-05-09 2021-03-05 삼성전자주식회사 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용
TWI690525B (zh) 2014-07-07 2020-04-11 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
EP3174854B1 (en) 2014-07-31 2022-08-24 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
EP3177311B1 (en) 2014-08-05 2024-10-30 Exelixis, Inc. Drug combinations of cabozantinib with proteasome inhibitor to treat multiple myeloma
US10208034B2 (en) 2014-12-25 2019-02-19 Ono Pharmaceutical Co., Ltd. Quinoline derivative
FR3039401B1 (fr) * 2015-07-31 2018-07-13 Les Laboratoires Servier Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr
CN106467541B (zh) * 2015-08-18 2019-04-05 暨南大学 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
WO2017181187A1 (en) 2016-04-15 2017-10-19 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
AU2017281083B2 (en) 2016-06-21 2022-01-27 Janssen Biotech, Inc. Cysteine engineered fibronectin type III domain binding molecules
CN110437145A (zh) * 2016-09-13 2019-11-12 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
CN107235897B (zh) * 2016-09-27 2019-08-16 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
US10597438B2 (en) 2016-12-14 2020-03-24 Janssen Biotech, Inc. PD-L1 binding fibronectin type III domains
WO2018111973A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd8a-binding fibronectin type iii domains
WO2018111978A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
CN119707932A (zh) 2017-01-26 2025-03-28 小野药品工业株式会社 喹啉衍生物的乙磺酸盐
EP3583943B1 (en) 2017-02-15 2024-09-18 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition
MA50251A (fr) 2017-09-08 2021-06-02 Taiho Pharmaceutical Co Ltd Agent antitumoral et potentialisateur d'effet antitumoral
JP7223998B2 (ja) 2017-10-13 2023-02-17 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
CN115192540A (zh) 2018-06-15 2022-10-18 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
EP3914356A1 (en) * 2019-01-25 2021-12-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
CN114786682B (zh) 2019-10-14 2024-07-16 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
CN115073367A (zh) * 2021-03-16 2022-09-20 南京科默生物医药有限公司 一种用作axl抑制剂的抗肿瘤化合物及其用途
BR112023021318A2 (pt) 2021-04-14 2023-12-19 Aro Biotherapeutics Company Conjugados de domínio fn3-sirna e usos dos mesmos
AU2022258566A1 (en) 2021-04-14 2023-10-12 Aro Biotherapeutics Company Cd71 binding fibronectin type iii domains
WO2024163400A1 (en) 2023-01-31 2024-08-08 Handa Oncology, Llc Improved cabozantinib compositions and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60203260T2 (de) * 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
PT2213661E (pt) * 2003-09-26 2011-12-15 Exelixis Inc Moduladores de c-met e métodos de uso
ITRM20030475A1 (it) * 2003-10-15 2005-04-16 Sipa Societa Industrializzazione P Rogettazione E Impianto e metodo per il condizionamento termico di oggetti
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
NZ569787A (en) * 2005-12-15 2011-07-29 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or FLT1 antagonist for treating cancer
WO2007081978A2 (en) * 2006-01-11 2007-07-19 Angion Biomedica Corporation Modulators of hepatocyte growth factor / c-met activity
EP2101759B1 (en) * 2006-12-14 2018-10-10 Exelixis, Inc. Methods of using mek inhibitors
CA2683559C (en) * 2007-04-13 2019-09-24 Dana Farber Cancer Institute, Inc. Methods for treating cancer resistant to erbb therapeutics
AU2007353779B2 (en) * 2007-05-17 2013-11-07 Genentech, Inc. Crystal structures of neuropilin fragments and neuropilin-antibody complexes
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
US9745278B2 (en) * 2007-09-10 2017-08-29 Boston Biomedical, Inc. Group of STAT3 pathway inhibitors and cancer stem cell pathway inhibitors

Also Published As

Publication number Publication date
CA2723699A1 (en) 2009-11-12
US20090274693A1 (en) 2009-11-05
EA201071268A1 (ru) 2011-06-30
US20130142790A1 (en) 2013-06-06
AU2009244453B2 (en) 2012-07-19
EP2274304A1 (en) 2011-01-19
AR071631A1 (es) 2010-06-30
BRPI0912582A2 (pt) 2015-07-28
TW201006829A (en) 2010-02-16
CN102083824A (zh) 2011-06-01
JP2011519941A (ja) 2011-07-14
KR20110004462A (ko) 2011-01-13
SG190623A1 (en) 2013-06-28
EP2274304A4 (en) 2012-05-30
UY31800A (es) 2009-11-10
AU2009244453A1 (en) 2009-11-12
EA020779B1 (ru) 2015-01-30
US20130150363A1 (en) 2013-06-13
IL209057A0 (en) 2011-01-31
MX2010012101A (es) 2010-11-30
CL2009001063A1 (es) 2010-09-24
WO2009137429A1 (en) 2009-11-12
ZA201007722B (en) 2011-08-31

Similar Documents

Publication Publication Date Title
PE20091832A1 (es) Combinacion farmaceutica de un inhibidor de cmet y axl y un inhibidor de erbb
CY1121699T1 (el) Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor
AR086144A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
PE20050963A1 (es) Compuestos derivados de 8-azoniabiciclo [3.2.1]octanos como antagonistas de receptores de acetilcolina muscarinicos
AR084001A1 (es) Monobactamas y su uso en el tratamiento de infecciones bacterianas
BR122012009489B8 (pt) processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
PE20160844A1 (es) Compuestos triciclicos como agentes anticancerigenos
PE20121815A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
NZ631477A (en) Substituted pyrrolidine-2-carboxamides
PE20171177A1 (es) Compuestos aminopirimidinilo inhibidores de jak
UY28755A1 (es) Compuestos
MX343264B (es) Ciertas amino-piridazinas, composiciones de las mismas y metodos de uso de los mismos.
CO6160229A2 (es) Ciclopenta [d] pirimidinas como inhibidores de proteina quinasa akt
UY28756A1 (es) Compuestos
BG104372A (en) (benzodioxan, benzofuran or benzopyran) derivatives possessing fundus relaxing properties
JO2972B1 (en) Piperidine / piperazine derivatives
PE20142456A1 (es) COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks
TW201204363A (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
UA98966C2 (ru) Производные бензазепина, пригодные для использования в качестве антагонистов вазопрессина
CO6460743A2 (es) Derivados de 7-aza-espiro[3.5]nonano-7-carboxilatos, su preparación y su aplicación en terapéutica
CO6400139A2 (es) Derivados de ciclopenta[c]pirool-2-carboxilatos, su preparación y su aplicación en terapéutica
AR066103A1 (es) Derivados de triazolopiridin - carboxamidas, su preparacion y su aplicacion en terapeutica
ATE554086T1 (de) Scopin-salze und deren verwendung in verfahren zur herstellung von n-demethyl-tiotropium und tiotropiumbromid
AR077367A1 (es) 2- carboxamida -cicloamino-ureas sustituidas
EA201591230A1 (ru) Композиция диклофенака

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed